Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
ExportLink to record
Permanent link

Direct link
BETA

Project

Project type/Form of grant
Project grant
Title [sv]
Behandling av inflammatorisk tarmsjukdom med anaerob odlad human intestinal mikrobiota; avancerad monitorering av tarminflammation
Title [en]
Treatment of inflammatory bowel disease with anaerobic cultured human intestinal microbiota; advanced monitoring of gut inflammation.
Abstract [en]
This is a new venue for treatment of inflammatory bowel disease (IBD) using luminally administered anaerobic cultured human intestinal microbiota (ACHIM) for healing of IBD. The overt inflammatory reaction in IBD is visualized with combo PET/MRI imaging before and after successfull treatment of IBD. The 11C-neurokinin-1 receptor ligand is used for visualization of neurokinin receptor up-regulation in inflammatory tissue, 18F-fludeoxyglucose is used for visualization of inflamed hypermetabolic tissue, while cellular accumulation of iron-loaded macrophages within precise anatomical structures is verified by MRI. This experimental setup will diagnose and monitor inflammatory reactions on a receptor, cellular, functional and morphological level. The wireless motility capsule SmartPill is used for for recording of luminal pH, motility and temperature, concomitant with gut permeability testing and plasma neurohormonal peptide release and a 40-plex cytokine/chemokine panel which will further add to the diagnostic feasibility on a functional level. From a biobank of 120 subjects and imaging will be done with PET/MRI in matched patients, before and after ACHIM treatment. Our project aims at quantifying the inflammatory condition in terms of IBD. Data on inflammation will be verified against colonoscopy with histopathology to mucosal healing. Results of ACHIM fecal microbiota transplantation and evaluation with PET-MRI plus gut permeability are unique in international gastroenterology.
Publications (2 of 2) Show all publications
Bedada, A. T., Gebremariam, T. H., Manyazewal, T., Birhan, Y. A., Dugul, T. T., Gebre, S. G., . . . Hellström, P. M. (2026). Oxidative stress index as a potent predictor of disease severity and inflammatory burden in hospitalized COVID-19 patients. Infectious Medicine, 5(2), Article ID 100261.
Open this publication in new window or tab >>Oxidative stress index as a potent predictor of disease severity and inflammatory burden in hospitalized COVID-19 patients
Show others...
2026 (English)In: Infectious Medicine, ISSN 2097-0684, Vol. 5, no 2, article id 100261Article in journal (Refereed) Published
Abstract [en]

Background

While the acute phase of the COVID-19 pandemic has passed, understanding its pathophysiology remains critical for managing long-term sequelae and future viral threats. Oxidative stress is a proposed key driver of COVID-19 severity, but its relationship with the dynamic inflammatory cascade and its value as a standalone biomarker requires further validation.

Methods

Case-control study was conducted to quantify systemic oxidative stress burden in 109 hospitalized COVID-19 patients (56 severe, 53 mild-moderate) and 112 healthy controls. Serum total oxidant status (TOS) and total antioxidant status (TAS) were measured, and the oxidative stress index (OSI) was calculated and correlated to the inflammatory mediators (IL-6, IL-8, IL-10, IP-10, CRP, SAA).

Results

COVID-19 patients exhibited a profound redox imbalance, characterized by elevated TOS and OSI, and depleted TAS compared to controls (p < 0.05). This imbalance was exacerbated in severe disease, where TOS and OSI were significantly increased. The OSI demonstrated superior diagnostic performance for disease severity (AUC = 0.90; 95% CI: 0.86–0.95) compared to TOS (AUC = 0.89) and TAS (AUC = 0.78). Crucially, both TOS and OSI showed strong positive correlations with inflammatory cytokines and acute-phase proteins (IL-6, IL-10, IP-10, CRP, SAA; all p < 0.001). After adjusting for age, time from symptom onset, and comorbidity burden (Charlson Comorbidity Index), multivariate analysis confirmed that high OSI was independently associated with disease severity (adjusted OR: 4.8; 95% CI: 1.9–12.1).

Conclusions

The OSI is a robust, integrative biomarker that strongly reflects COVID-19 severity and is closely linked to the hyperinflammatory state. The OSI is strongly correlated with increased inflammatory cytokines and acute-phase proteins in acute COVID-19.

Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
SARS-CoV-2, Oxidative stress, Biomarker, Inflammation, Cytokine storm
National Category
Infectious Medicine
Identifiers
urn:nbn:se:uu:diva-592057 (URN)10.1016/j.imj.2026.100261 (DOI)001790926900001 ()42199648 (PubMedID)2-s2.0-105039517712 (Scopus ID)
Funder
Swedish Research Council, 2017-02243
Available from: 2026-06-25 Created: 2026-06-25 Last updated: 2026-06-25Bibliographically approved
Webb, D.-L., Hage, C., Ljung-Faxén, U., Pironti, G., Thorvaldsen, T., Andersson, D. C., . . . Hellström, P. M. (2026). Post-prandial acyl ghrelin infusion in heart failure patients increases gastric emptying rate. Naunyn-Schmiedeberg's Archives of Pharmacology, 399, 13437-13443
Open this publication in new window or tab >>Post-prandial acyl ghrelin infusion in heart failure patients increases gastric emptying rate
Show others...
2026 (English)In: Naunyn-Schmiedeberg's Archives of Pharmacology, ISSN 0028-1298, E-ISSN 1432-1912, Vol. 399, p. 13437-13443Article in journal (Refereed) Published
Abstract [en]

Acyl ghrelin increases cardiac output (CO) and contractility in patients with heart failure with reduced ejection fraction (HFrEF). In healthy humans, acyl ghrelin increases gastric emptying rate (GER) and hunger, a potential add-on benefit for HFrEF patients suffering from cachexia with symptoms of delayed gastric emptying and loss of appetite. The aim of this study was to determine if post-prandial acyl ghrelin infusion increases GER and hunger in HFrEF patients compared to CO. HFrEF patients (n = 29) arrived fasted and received a 500-kcal breakfast followed by 1.5 g paracetamol. They next received placebo (vehicle, n = 15) or acyl ghrelin infusion (0.1 μg/kg/min, n = 14) for 120 min. Blood was tapped for plasma at 0, 30, 60, 120, and 150 min into the meal. Hunger scores and CO were recorded. Plasma paracetamol was measured to assess GER. Paracetamol concentration peaked at 30 min in 8 of 14 (57%) in the treatment group versus 1 of 15 (7%) in the placebo group (Mann-Whitney test, P = 0.004). Remaining patients peaked at later time points. The acyl ghrelin treatment group data was segregated into rapid (peak at 30 min, n = 8) and slow (peak > 30 min, n = 6) GER sub-groups. The rapid sub-group had an acyl ghrelin treatment effect on CO (one-way repeat measures, P < 0.001) and the highest median increase in hunger across all time points. Acyl ghrelin increases GER and in tandem with increasing CO. Effects on hunger are more difficult to resolve due to variability in subjective scores. Some HFrEF patients may benefit from this add-on effect.

Place, publisher, year, edition, pages
Springer Nature, 2026
Keywords
Ghrelin, Heart failure, Gastroparesis, Gastric emptying, Acetaminophen, Gastrointestinal agents
National Category
Cardiology and Cardiovascular Disease Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-602336 (URN)10.1007/s00210-026-05245-5 (DOI)001724347000001 ()41886075 (PubMedID)2-s2.0-105033717288 (Scopus ID)
Funder
Uppsala UniversityErik, Karin och Gösta Selanders FoundationO.E. och Edla Johanssons vetenskapliga stiftelseSwedish Research Council, 523–2014-2336Swedish Research Council, 2018-0899Swedish Heart Lung Foundation, 20150557Swedish Heart Lung Foundation, 20190310Stockholm County Council, 20140220Karolinska Institute, 2–70/2014
Available from: 2026-10-29 Created: 2026-10-29 Last updated: 2026-10-29Bibliographically approved
Principal InvestigatorHellström, Per
Coordinating organisation
Uppsala University
Funder
Period
2018-01-01 - 2020-12-31
National Category
Gastroenterology and Hepatology
Identifiers
DiVA, id: project:5911Project, id: 2017-02243_VR

Search in DiVA

Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar